The short version
- In a drug-maker-funded analysis of tirzepatide trials, women lost about 23% of body weight after menopause versus 26% before it. Menopause did not block the effect.
- Hormone therapy users lost more weight on a GLP-1 drug in several observational studies. The gap shrank as the studies got larger, and none was a randomized trial, so cause is unproven.
- About a quarter to a third of the weight lost on semaglutide or tirzepatide is lean mass, similar to weight lost through intensive diet and exercise. Lean mass is not the same as muscle.
- Weight loss itself is linked to bone loss, and no trial built around menopausal women has measured bone on these drugs. Strength training, protein, calcium and vitamin D, and a conversation about a bone density scan are the practical steps.
- If you use oral hormone therapy, ask your prescriber whether the route matters. The manufacturer says oral HRT has not been studied with tirzepatide, and British menopause specialists suggest considering non-oral options.
- After semaglutide was stopped in one trial, participants regained about two-thirds of the weight they had lost within a year.
Why menopause changes the GLP-1 conversation
The menopause transition changes the body in ways that overlap with what these drugs do. In a large US study that scanned women repeatedly, fat gain doubled in speed and lean mass began to fall when the transition started, and both leveled off about two years after the final period.21 Estrogen decline also speeds bone turnover, which is why the same years raise the risk of osteoporosis.4
Losing weight with any method removes some lean mass and some bone along with fat. AARP reports that about one in five women aged 50 to 64 has taken a GLP-1 drug, the highest use of any age group.9 Its coverage of a Menopause Society annual meeting also notes that researchers do not yet know whether the muscle and bone loss that comes with GLP-1 treatment is more pronounced in women than in men.9 That gap in knowledge is the reason this article exists.
Need more than general advice? Our community offers professional, personalized nutrition and exercise plans. Join the Fit Over 40 community
Do Ozempic, Wegovy and Zepbound work after menopause?
The best answer so far comes from a post hoc analysis of the SURMOUNT tirzepatide trials, which included 2,542 women. Women lost a lot of weight in every reproductive stage. In SURMOUNT-1, the largest trial, the average loss was about 26% before menopause, 23% during the transition and 23% after menopause, compared with 2% to 3% on placebo in the premenopausal and perimenopausal groups.14
- What it supports: menopause does not appear to switch the drug off.
- What to keep in mind: the analysis was post hoc, it assigned menopause stage retrospectively, and the drug's maker paid for it.
Trial averages are best-case figures. Results in everyday care can differ, and that is true at every age.
Does hormone therapy make GLP-1 weight loss better?
This is the question behind many headlines. Three studies from the same Mayo Clinic group are worth reading side by side, because the pattern across them is the interesting part.
| Study | Who | Weight loss with hormone therapy vs without |
|---|---|---|
| Semaglutide, Menopause 20243 | 106 postmenopausal women, only 16 using hormone therapy | About 16% vs 12% at 12 months. 85.7% vs 58.1% reached a 10% loss |
| Tirzepatide, Lancet 20261 | 120 postmenopausal women (40 on hormone therapy, 80 matched), about 18 months on average | 19.2% vs 14.0%, a 5.2 percentage point gap. 45% vs 24% reached 20% loss |
| Semaglutide and tirzepatide, Menopause Society meeting 20264,5 | About 3,900 midlife women: nearly 2,400 on semaglutide, nearly 1,500 on tirzepatide | Semaglutide at one year: 11% vs 9.5%. Tirzepatide: same direction early on, not statistically significant |
Source: the studies cited in each row. The 2026 meeting data are a conference presentation and have not been through full journal peer review.
Two things stand out. First, the headline figure of "35% more weight loss" is a relative number; in the tirzepatide study it was a gap of 5.2 percentage points, and in the much larger meeting analysis the gap with semaglutide at one year was about 1.5 points.1,4 It is a common pattern for effects that look large in small studies to shrink as samples grow.
Second, the researchers themselves list reasons the result may not be about the hormones. Women who use hormone therapy may differ in health habits and health care access, a "healthy user" effect, and symptom relief may improve sleep and mood enough to make eating and exercise changes easier to keep.1,4 The lead investigators say the findings can show an association, not cause, and they plan a randomized trial.2 The lead author has pointed to early rodent studies in which estrogen enhanced the body's own GLP-1 signaling, but that link has not been shown in women on these drugs.1
How much muscle do you lose on a GLP-1 drug?
Every large weight loss costs some lean mass. The numbers differ by drug and study.
| Drug | Share of weight lost that was lean mass |
|---|---|
| Semaglutide | About 35% (95% CI 31.5 to 38.9) |
| Tirzepatide | About 25% (95% CI 22.8 to 28.0) |
| Liraglutide | About 27% (95% CI 23.1 to 30.5) |
Source: 2026 meta-analysis of randomized trials comparing incretin drugs with lifestyle interventions.7 The same analysis found the lean share of weight lost was broadly comparable to intensive lifestyle weight loss.7 In the SURMOUNT-1 body composition substudy, about 75% of the weight lost on tirzepatide was fat and 25% lean mass, and the proportions were similar across age groups, though only 41 participants aged 50 to 64 were in the age analysis.6
Why "lean mass" is not the same as muscle
The scans used in these trials count organs, water, connective tissue and bone mineral along with muscle. A review of the evidence found large differences between studies, from about 15% of weight lost to 40% to 60%, and said MRI-based work suggests muscle changes are roughly in proportion to the weight lost.8 The same review flagged older age and disease severity as factors that could matter when judging who is at risk of sarcopenia.8 Menopause is a stage where muscle is already under pressure, which is why women in these years should not assume the average applies to them.
What protects muscle: protein and strength training
No large trial has yet tested this in menopausal women taking GLP-1 drugs. The advice rests on weight loss research in general and on emerging GLP-1 work.
- Protein: a consensus commentary summarized in July 2026 recommended more than 1.2 grams per kilogram per day, spread across meals.11
- Resistance training: the same commentary paired protein with aerobic activity and structured strength training.11 At the American Diabetes Association 2026 meeting, a trial called S-LITE was described in which adding supervised resistance and aerobic training to liraglutide produced greater weight loss and allowed lean mass gain.12
- Tracking: the 2026 meta-analysis concluded muscle can be substantially preserved by combining training, adequate protein and body composition monitoring.7
The LEAN-PREP trial is testing this directly: 232 people starting semaglutide or tirzepatide are being assigned to usual care, a protein target of 1.6 grams per kilogram, resistance exercise, or both for six months.22 Results are not available yet.
What those protein numbers look like
| Your weight | 1.2 g per kg per day | 1.6 g per kg per day |
|---|---|---|
| 130 lb (59 kg) | about 71 g | about 94 g |
| 150 lb (68 kg) | about 82 g | about 109 g |
| 170 lb (77 kg) | about 93 g | about 123 g |
| 190 lb (86 kg) | about 103 g | about 138 g |
These are our calculations from the figures in the sources. The 1.2 figure is a floor in the consensus commentary and the 1.6 figure is a trial target, not a personal prescription. Appetite on these drugs can be so low that hitting a protein number is the hard part, so small, protein-first meals help. People with kidney disease have different protein limits. See our guides to protein for women over 50 and strength training after 40.
What about bone? The question with the least data
Bone is where this topic has the largest hole. Weight loss is associated with bone loss, and a meta-analysis of placebo-controlled trials found only two that measured bone density with GLP-1 based drugs.24 Evidence from large health records is mixed. One analysis of fragility fractures found a lower risk among people with type 2 diabetes but a higher risk among people without it, who are more like people taking these drugs for weight loss alone (hazard ratio 1.13, 95% CI 1.04 to 1.23).10 Its authors suggested that baseline bone density assessment and monitoring may be warranted.23 Because it is observational, it cannot prove the drugs caused the difference, and it did not look at menopausal women specifically.
For menopausal women there is a stacking effect that no study has measured: estrogen decline, weight loss and less mechanical load on the skeleton all arrive together. In Healio's report on the 2026 meeting findings, the researchers said bone assessment should reflect each woman's risk factors, because both estrogen decline and substantial weight loss can affect bone.4
What is reasonable to do
- Ask about a bone density scan. The US Preventive Services Task Force recommends screening for women 65 and older, and for postmenopausal women under 65 with risk factors after a risk assessment.20
- Lift, progressively. In the LIFTMOR trial, 101 postmenopausal women with low bone mass (average age 65) trained twice a week for eight months with supervised heavy lifting and impact exercises. They improved bone density and function compared with a low-intensity program, with one minor adverse event reported.19 The program was supervised, gradual and screened, and the results apply to that setting.
- Get calcium and vitamin D from food first. See calcium and vitamin D after menopause and osteoporosis after menopause.
- Know what hormone therapy does for bone. The 2022 position statement says it has been shown to prevent bone loss and fracture, with a risk-benefit picture that depends on age and time since menopause.18
Taking oral HRT with Ozempic, Wegovy or Zepbound
These drugs slow the emptying of the stomach, which can change how oral medicines are absorbed. For tirzepatide, a review of the trial data found the delay was largest after the first dose and eased afterward, and that tirzepatide appeared to affect oral birth control absorption more than other GLP-1 drugs.16 The manufacturer's medical information says oral hormone replacement therapy has not been studied with tirzepatide.15
Because of that gap, the British Menopause Society published a tool for clinicians in April 2025. Its main points, which combine trial data with expert opinion:17
- These drugs may reduce absorption of any oral component of HRT.
- If a woman on oral estrogen starts one, consider switching to transdermal estrogen.
- A non-oral progestogen is preferable, for example a combined patch or a levonorgestrel intrauterine device, because the main concern is endometrial protection.
- There is no trial data to guide an oral progestogen dose, so the tool offers expert-opinion suggestions for clinicians, and unscheduled bleeding should be assessed following national guidance.
This is UK professional guidance. Our searches did not turn up an equivalent statement from a US society, so US prescribers may handle it differently.
What happens when you stop
In the STEP 1 extension, people who stopped semaglutide after 68 weeks had lost 17.3% of their weight; a year later they had regained 11.6 percentage points, about two-thirds, and the improvements in blood pressure, blood sugar and lipids largely reverted toward baseline.13 People who had been on placebo with lifestyle changes regained nearly everything they had lost, which was small.13 The extension had no active lifestyle support during the off-treatment year, and it was funded by the drug's maker. It was not a menopause study, but it is the reason strength and eating habits built while on treatment matter: they are the part you keep control of.
What we still do not know
- Whether hormone therapy genuinely improves GLP-1 results. A randomized trial is planned.2
- Whether the type, dose and route of hormone therapy matter. The tirzepatide study pooled all types together.1
- Whether muscle and bone loss on these drugs is greater in menopausal women than in men or younger women.9
- Whether exercise and protein targets work as well in menopausal women as they do in the general population. The LEAN-PREP trial should help.22
- How oral hormone therapy absorption changes in practice, and what dose adjustments are needed, if any.17
Questions to take to your prescriber
- Given my age and bone risk factors, should I have a bone density scan before or during treatment?
- Am I a candidate for hormone therapy for my symptoms, and would the route matter alongside this drug?
- How will we track muscle, not just the scale, for example grip strength, a waist measurement or a body composition scan?
- What protein target suits me, given my kidney function and appetite?
- What is the plan if I stop, and what do I keep doing so the progress holds?
Related guides:
- How to lose weight after 50: what the evidence supports
- Best exercises for women over 50
- How to measure your waist
Common questions
Do Ozempic, Wegovy and Zepbound work differently after menopause?
Not in the trial data we have. A post hoc analysis of three tirzepatide trials in 2,542 women found large weight loss in every reproductive stage, about 26% before menopause and 23% after it in the largest trial.14 The analysis was funded by the drug's maker and menopause stage was assigned after the fact.
Should I take hormone therapy to lose more weight on a GLP-1 drug?
No. Hormone therapy is prescribed for symptoms such as hot flashes and for bone protection in suitable candidates, not for weight loss.18 The studies linking it to larger weight loss are observational, and the researchers themselves say they cannot show that hormone therapy caused the difference.2
How much muscle will I lose on a GLP-1 drug?
Pooled trial data put lean mass at about 35% of the weight lost on semaglutide and about 25% on tirzepatide, which is broadly similar to intensive lifestyle weight loss.7 Lean mass includes organs, water and bone as well as muscle.8 Resistance training and enough protein are the tools with the best support for protecting muscle during weight loss.7,11
How much protein do I need on Ozempic, Wegovy or Zepbound?
A consensus commentary summarized in July 2026 advised more than 1.2 grams per kilogram of body weight per day, spread across meals, together with aerobic activity and structured strength training.11 A trial now recruiting is testing 1.6 grams per kilogram for people starting these drugs.22
Do GLP-1 drugs cause bone loss?
Weight loss from any cause is linked to bone loss, and the effect of these drugs on bone in menopausal women has not been settled. A meta-analysis found only two eligible placebo-controlled trials that measured bone density.24 One large observational analysis found a lower fracture risk in people with type 2 diabetes and a higher risk in people without it.10
Can I take oral estrogen or progesterone with Zepbound or Wegovy?
The manufacturer's medical information says oral hormone replacement therapy has not been studied with tirzepatide.15 British Menopause Society guidance says these drugs delay gastric emptying and may reduce absorption of oral HRT, and suggests considering transdermal estrogen and a non-oral progestogen.17 That guidance is written for UK clinicians and rests partly on expert opinion. Prescribers need to know about both medicines, and unexpected bleeding should be reported.
What happens if I stop a GLP-1 drug?
In the STEP 1 extension, people who stopped semaglutide regained 11.6 percentage points of the 17.3% they had lost within a year, about two-thirds, and most heart and metabolic improvements drifted back toward baseline. No active lifestyle support was provided in that off-treatment year.13
References
- Castaneda R, Bechenati D, Tama E, et al. The role of menopause hormone therapy in modulating tirzepatide-associated weight loss in postmenopausal women with overweight or obesity: a retrospective cohort study. Lancet Obstet Gynaecol Womens Health. 2026;2(2):e118-e128. https://doi.org/10.1016/S3050-5038(25)00145-1
- Mayo Clinic News Network. New study links combination of hormone therapy and tirzepatide to greater weight loss after menopause. January 2026. https://newsnetwork.mayoclinic.org/discussion/new-study-links-combination-of-hormone-therapy-and-tirzepatide-to-greater-weight-loss-after-menopause
- Hurtado MD, Tama E, Fansa S, et al. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause. 2024;31(4):266-274. https://doi.org/10.1097/GME.0000000000002310
- Healio. Hormone therapy plus GLP-1 may equal greater, sustainable weight loss for menopausal women. October 23, 2026. Reports research presented at The Menopause Society 2026 annual meeting. https://www.healio.com/news/womens-health-ob-gyn/20261023/hormone-therapy-plus-glp1-may-equal-greater-sustainable-weight-loss-for-menopausal-women
- HealthDay via MedicineNet. Menopause hormone therapy might boost GLP-1 weight loss results, study says. October 21, 2026. https://www.medicinenet.com/menopause_hormone_therapy_might_boost_glp1s/news.htm
- Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025. https://doi.org/10.1111/dom.16275
- Lean mass changes with incretin therapy versus lifestyle intervention: a systematic review and meta-analysis of randomised controlled trials. Diabetes Obes Metab. 2026;28(6):4818-4827. https://pubmed.ncbi.nlm.nih.gov/41877354/
- Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(Suppl 4):16-27. https://pubmed.ncbi.nlm.nih.gov/38937282/
- AARP. From brain fog to weight loss: 5 menopause research updates. https://www.aarp.org/health/conditions-treatments/menopause-research-findings/
- Drug Topics. Study links GLP-1s to lower fragility fractures in adults with diabetes. July 30, 2026. https://www.drugtopics.com/view/study-links-glp-1s-to-lower-fragility-fractures-in-adults-with-diabetes
- Drug Topics. How GLP-1 therapies could impact bone density, muscle loss. July 6, 2026. https://www.drugtopics.com/view/how-glp-1-therapies-could-impact-bone-density-muscle-loss
- AJMC. GLP-1 therapies in 2026: beyond blood sugar and the scale. June 9, 2026. Report from the American Diabetes Association 2026 Scientific Sessions. https://www.ajmc.com/view/glp-1-therapies-in-2026-beyond-blood-sugar-and-the-scale
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. https://pubmed.ncbi.nlm.nih.gov/35441470/
- Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. Obesity (Silver Spring). 2025;33(5):851-860. https://pubmed.ncbi.nlm.nih.gov/40074721/
- Eli Lilly and Company, Medical Information. Can Zepbound (tirzepatide) be used with oral contraceptives or hormone replacement therapy? Reviewed February 25, 2026. https://medical.lilly.com/us/products/answers/can-zepbound-tirzepatide-be-used-with-oral-contraceptives-or-hormone-replacement-therapy-211019
- The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception. J Am Pharm Assoc. 2024;64(1):204-211. https://pubmed.ncbi.nlm.nih.gov/37940101/
- British Menopause Society. Use of incretin-based therapies in women using hormone replacement therapy (HRT): tool for clinicians. April 2025. https://thebms.org.uk/wp-content/uploads/2025/05/23-BMS-TfC-Use-of-incretin-based-therapies-APRIL2025-E.pdf
- The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. https://pubmed.ncbi.nlm.nih.gov/35797481/
- Watson SL, Weeks BK, Weis LJ, et al. High-intensity resistance and impact training improves bone mineral density and physical function in postmenopausal women with osteopenia and osteoporosis: the LIFTMOR randomized controlled trial. J Bone Miner Res. 2018;33(2):211-220. https://pubmed.ncbi.nlm.nih.gov/28975661/
- US Preventive Services Task Force. Osteoporosis to prevent fractures: screening. Final recommendation statement, January 14, 2025. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/osteoporosis-screening
- Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4(5):e124865. https://doi.org/10.1172/jci.insight.124865
- ClinicalTrials.gov. LEAN mass preservation with resistance exercise and protein during semaglutide/tirzepatide therapy (LEAN-PREP). NCT06885736. https://clinicaltrials.gov/study/NCT06885736
- Managed Healthcare Executive. Large study finds GLP-1 drugs may lower fracture risk in type 2 diabetes. September 22, 2026. https://www.managedhealthcareexecutive.com/view/large-study-finds-glp-1-drugs-may-lower-fracture-risk-in-type-2-diabetes
- GLP-1 receptor agonist-based therapies and DXA-acquired musculoskeletal health outcomes: a focused meta-analysis of placebo-controlled trials. Obesity Reviews / Wiley, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11774015
Every health claim above links to its source. It is general information and cannot take your personal history into account, so use it to prepare for a conversation with your own clinician.
Spotted an error? Tell us and we will check it.